Sanofi argued that the patents were invalid as a matter of law under Section 112 of the Patent Act because they sought to claim for Amgen’s exclusive …
Sanofi argued that the patents were invalid as a matter of law under Section 112 of the Patent Act because they sought to claim for Amgen’s exclusive …